Table 1

Demographic characteristics of patients with DME who received either anti-VEGF agents or a DEX-implant during the study period

VariableAnti-VEGF
(n=182)
DEX-implant
(n=414)
P value
Age, mean (SD), years58.6 (12.6)59.6 (10.8)0.406
Age, n (%), years0.409
 18–3910 (5.5)22 (5.3)
 40–4928 (15.4)46 (11.1)
 50–5954 (29.7)127 (30.7)
 60–6954 (29.7)149 (36.0)
 70+36 (19.8)70 (16.9)
Gender, n (%)0.197
 Male101 (55.5)206 (49.8)
 Female81 (44.5)208 (50.2)
CCI, n (%)0.083
 033 (18.1)44 (10.6)
 155 (30.2)130 (31.4)
 243 (23.6)103 (24.9)
 351 (28.0)137 (33.1)
Health plan type, n (%)*0.0003
 NHI157 (86.3)393 (94.9)
 MAP25 (13.7)21 (5.1)
  • Age, gender and health plan type are analysed based on the index date. The CCI score is calculated for the 12 months from the start of the index date. P value estimated based on the χ² (categorical variables) and t-test (continuous variable).

  • *Korea has the NHI system for the general population and the MAP for the low-income people. The NHI system is for the entire population residing within the territory of Korea except for beneficiaries of medical aid.

  • anti-VEGF, antivascular endothelial growth factor; CCI, Charlson Comorbidity Index; DEX-implant, dexamethasone intravitreal implant; DME, diabetic macular oedema; MAP, Medical Aid Program; NHI, National Health Insurance.